It is assumed that, in patients with end-stage chronic kidney disease (stages 4-6), the reabsorption of 1,5-AG is decreased because of the reduction in SGLT4 and aggravated damage of glucose co transporters, but there is no actual data to confirm this hypothesis to date [55]. This evidence concerns the gene SLC5A9 and chronic kidney disease.